[Market Feature] DreamCIS Surges on Potential to Lead Organoid Sector Backed by Overwhelming Results

DreamCIS is showing strong performance. This is interpreted as being influenced by expectations in the securities market that the company could emerge as a leading stock in the organoid sector, based on its overwhelming financial results.

As of 11:11 a.m. on December 18, DreamCIS was trading at 6,450 won, up 19.22% from the previous day.

DreamCIS is a global contract research organization (CRO) specializing in playing an essential role throughout the entire new drug development process. It is the only company in Korea to offer a one-stop solution that covers everything from preclinical studies to license in and out. With global CRO company Tigermed as its largest shareholder, DreamCIS also has a distinct competitive edge in leveraging overseas networks.

Choi Jaeho, a researcher at Briars Insight, stated, "This year, DreamCIS decided to acquire a stake in the American organoid company Curibio, and by January next year, it will secure a 23.7% share to become the largest shareholder." He added, "Curibio counts global big pharma companies such as Roche, Novo Nordisk, and Eli Lilly among its clients, so it is expected to directly benefit from the expanding demand for alternatives to animal testing."

The organoid industry environment is also considered favorable. He explained, "As policies to replace animal testing are spreading, especially in the United States and Europe, the clinical use of organoids is rapidly increasing. DreamCIS has a structure that allows it to secure differentiated competitiveness by combining its CRO business with organoid technology."

He continued, "Unlike many domestic organoid-related companies, which are recording losses, DreamCIS is already generating stable profits. Given that it has both a strong financial foundation and new growth drivers, the current valuation is in an undervalued range." He further added, "If the expansion of the global CRO business and the effects of the organoid acquisition are fully reflected, the company's mid- to long-term growth story will be further strengthened."